Bedrosian Camille L 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Crinetics (CRNX) Director Camille Bedrosian Receives Awards
What Happened
Camille L. Bedrosian, a member of Crinetics Pharmaceuticals' board of directors, was awarded equity on June 18, 2026: 5,925 restricted stock units (RSUs) and a 9,730-share derivative award (stock option-style grant). Both awards were reported at $0.00 per share (grant awards, not open-market purchases or sales).
Key Details
- Transaction date: 2026-06-18; Filing date: 2026-06-22 (filed within typical 2-business-day window).
- Awards: 5,925 RSUs (non-derivative) and 9,730 shares reported as a derivative award. Reported price: $0.00 (grant).
- Vesting: RSUs vest 100% on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders, subject to continued board service. The derivative (stock option) vests on the same schedule.
- Shares owned after the transaction: not provided in the supplied data.
- Nature of transaction: compensation/grant — not an indicator of a purchase or sale; no immediate sale or cashless exercise reported.
Context
RSUs represent the right to receive shares upon vesting; the derivative award is a stock-option-style grant that must vest before exercisability. These are routine board compensation grants and do not reflect an open-market buy or sell by the director.
Insider Transaction Report
Form 4
Bedrosian Camille L
Director
Transactions
- Award
Common Stock
[F1]2026-06-18+5,925→ 22,225 total - Award
Stock Option (Right to Buy)
[F2]2026-06-18+9,730→ 9,730 totalExercise: $35.87Exp: 2036-06-18→ Common Stock (9,730 underlying)
Footnotes (2)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
- [F2]The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Signature
/s/ Tobin Schilke, as attorney-in-fact|2026-06-22